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Cellular glycosylation affects 
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Alterations in protein glycosylation are a key feature of oncogenesis and have been shown to affect 
cancer cell behaviour perturbing cell adhesion, favouring cell migration and metastasis. This study 
investigated the effect of N-linked glycosylation on the binding of Herceptin to HER2 protein in breast 
cancer and on the sensitivity of cancer cells to the chemotherapeutic agent doxorubicin (DXR) and 
growth factors (EGF and IGF-1). The interaction between Herceptin and recombinant HER2 protein 
and cancer cell surfaces (on-rate/off-rate) was assessed using a quartz crystal microbalance biosensor 
revealing an increase in the accessibility of HER2 to Herceptin following deglycosylation of cell 
membrane proteins (deglycosylated cells Bmax: 6.83 Hz; glycosylated cells Bmax: 7.35 Hz). The sensitivity 
of cells to DXR and to growth factors was evaluated using an MTT assay. Maintenance of SKBR-3 cells 
in tunicamycin (an inhibitor of N-linked glycosylation) resulted in an increase in sensitivity to DXR 
(0.1 μM DXR P < 0.001) and a decrease in sensitivity to IGF-1 alone and to IGF-1 supplemented with 
EGF (P < 0.001). This report illustrates the importance of N-linked glycosylation in modulating the 
response of cancer cells to chemotherapeutic and biological treatments and highlights the potential of 
glycosylation inhibitors as future combination treatments for breast cancer.
Aberrant protein glycosylation is a well-established event in oncogenesis; shown to correlate with metastasis 
formation and resulting from changes in the expression levels and location of glycosyltransferases1–3. Our lab-
oratory and others have identified cancer-associated glycoproteins that exhibit aberrant glycosylation4–6, such 
glycoproteins include mucins (for example MUC17), integrins8 and cadherins9. Despite our understanding of the 
glycosylation changes occurring in cancer the effect on the binding of drugs to cell surface glycoproteins and on 
sensitivity of cancer cells to chemotherapeutic agents remains relatively poorly explored.
The human epidermal growth factor receptor 2 (HER2) protein, a member of the tyrosine kinase receptor 
family, is over-expressed in 25–30% of breast cancers, correlating with poor patient prognosis10. On binding to 
epidermal growth factor (EGF), HER2 can form homo- or heterodimers (with HER1, HER3 or HER4) triggering 
a series of events leading to the activation of members of the MAPK and PI3 kinase/AKT pathways. The overex-
pression of HER2 results in the constitutive activation of these pathways and cell proliferation. HER2 has been 
targeted with the monoclonal antibody drug Herceptin (Trastuzumab, Roche, Welwyn Garden City, UK) which 
upon binding induces a cytostatic effect associated with G1 arrest11. In a murine model, Herceptin was also shown 
to induce antibody dependent cell-mediated cytotoxity12.
Whilst the development of biological drugs such as Herceptin represent a breakthrough in the treatment of 
cancer, a significant number of HER2 positive patients either do not respond to, have innate, or develop acquired 
resistance to the treatment13. Herceptin resistance may arise - amongst others - as a result of epidermal growth 
factor (EGF) signalling through other HER receptors14, or signalling via the insulin-like growth factor receptor 
(IGFR)15,16 or through the activation of the PI3K/mTOR pathway17. A further proposed mechanism for Herceptin 
resistance is the physical blockade or masking of the HER2 receptor18, for example, the MUC4 molecule with its 
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extended carbohydrate structure appears to serve as a barrier for biomolecular interactions in the extracellular 
environment19,20 and over-expression of MUC4 in the Herceptin resistant breast cancer cell line JIMT-1 has been 
shown to lead to diminished Herceptin binding and isolation of the receptor from its normal interaction and 
activation partner21.
The chemotherapeutic agent DXR, a member of the anthracycline family of antibiotics22 has been used in 
combination therapies and as a front-line treatment for lymphoma, ovarian cancer, lung and breast cancer23. 
Again, innate and acquired resistance to DXR, as well as to other chemotherapeutic agents, remains a major 
obstacle to the successful treatment of cancer24. As cell surface proteins are often heavily glycosylated it has been 
postulated that such glycosylation may affect epitope accessibility and drug binding to receptor proteins, similarly, 
the glycocalyx might affect the sensitivity of cancer cells to chemotherapeutic agents.
In this study it was hypothesised that N-linked glycosylation might impede the binding of Herceptin to HER2 
in breast cancer and alter cancer cell sensitivity to DXR and growth factors. To study Herceptin-HER2 binding 
a cell based quartz crystal microbalance (QCM) system with adherent cancer cells grown on the surface of a 
biosensor chip was used. The cell-chip enabled an evaluation of the kinetics of interaction between Herceptin 
and HER2 in a quasi-physiological environment25–27. In contrast to conventional systems, where single receptors 
such as glycoprotein entities are investigated, the cell based QCM enables drug-receptor interactions to be stud-
ied in the presence of the other biomolecules present at the cell surface. The interaction between Herceptin and 
SK-OV-3 cells (a human ovarian carcinoma cell line) was recently investigated using this approach28 and we used 
the QCM-based system to study Herceptin binding to the HER2-over-expressing breast cancer cell line SKBR-329  
as well as to recombinant HER2 (rHER2) protein and to evaluate the effect of deglycosylation on Herceptin 
binding. In addition, breast cancer cells were grown in the presence of tunicamycin, an antibiotic that blocks 
the transfer of GlcNAc-1-P to dolichol-P, an essential early step in the intracellular production of N-linked gly-
cans. The reduction in cell surface glycosylation following tunicamycin treatment was evaluated using the lec-
tins wheat germ agglutinin (WGA) and Concanavilin A (Con A), carbohydrate binding proteins recognising 
N-linked glycans. The sensitivity of cancer cells to growth factors: EGF and IGF-1 alone and in combination, was 
evaluated following tunicamycin treatment and the role of glycosylation on sensitivity to DXR was determined. 
In summary, the current study evaluated the role of glycosylation on the binding of Herceptin and the sensitivity 
of breast cancer cells to DXR. In addition, the role of glycosylation on cellular sensitivity to growth factors (EGF, 
IGF-1) was evaluated.
Results
The binding of Herceptin to BT474, ZR-751, MCF-7 and SKBR-3 breast cancer cells was assessed using immuno-
fluorescence and confocal microscopy (Fig. 1). BT474 and ZR-751 showed the least binding to Herceptin while 
MCF-7 and SKBR-3 cells bound to Herceptin more intensely with SKBR-3 showing the most intense staining 
amongst these cell lines. When SKBR-3 cells were incubated with an anti-cerbB-2 antibody, as expected, the cells 
exhibited a much more intense staining pattern due to greater accessibility of the HER2 epitope to the antibody 
compared with accessibility to Herceptin. All subsequent experiments in which the kinetics of Herceptin binding 
was assessed were performed with SKBR-3 cells.
To assess cellular N-linked glycosylation, the lectin Con A from jack bean was employed in conjunction with 
fluorescence microscopy this confirmed the presence of N-linked glycans located predominately in the perinu-
clear region of the cytoplasm, consistent with intracellular trafficking of glycoproteins through the endoplasmic 
reticulum and Golgi apparatus (Fig. 2A). Binding of Herceptin was observed on the cell surface of SKBR-3 in 
focal regions and at cell junctions (Fig. 2B). Chemical treatment of SKBR-3 cells with sodium periodate (20 and 
40 mM) to deglycosylate (oxidise) the glycans resulted in a significant decrease in Con A binding and a significant 
increase in Herceptin binding (p < 0.05), this change in Herceptin binding led to the experiments below in which 
the kinetics of Herceptin binding at the cell surface was investigated. The result of experiments undertaken to 
deglycosylate rHER2 protein are shown in Supplementary Figure 1.
Herceptin/Con A binding to SKBR3 cells and to rHER2 protein. Similar dissociation constant, affinity 
values, (KD) of 0.56 nM and 0.51 nM were observed for Herceptin binding to rHER2 protein and to SKBR-3 cells 
respectively (Table 1). An increase in the association rate constant (ka) for Herceptin was observed when rHER2 
and SKBR-3 cells were deglycosylated with 20 mM sodium periodate (untreated cells: 2.46 E+5 M−1s−1; treated 
cells: 4.31 E+5 M−1s−1; untreated protein: 3.36 E+5 M−1s−1; treated protein: 6.61 E+5 M−1s−1). However, dissoci-
ation rate constants (kd) for Herceptin were also increased when rHER2 and SKBR-3 cells deglycosylated with 
20 mM sodium periodate (untreated cells: 1.26 E−4 s−1; treated cells: 3.42 E−4 s−1; untreated protein: 1.91 E−4 s−1; 
treated protein: 2.41 E−4s−1). The HER2 binding capacity, Bmax, for Herceptin also increased after deglycosylation 
of SKBR-3 cells and rHER2 protein (Fig. 3 and Table 1).
Unsurprisingly, the kinetics of Con A interaction at the SKBR-3 cell surface were significantly reduced when 
cells were treated with 20 mM sodium periodate. The dissociation rate constant, kd, increased more than a thou-
sand fold in the treated cells, Fig. 4 and Table 2 (untreated cells: 8.9 E−6 s−1; treated cells: 1.93 E−3 s−1) and as a 
result the affinity, KD, was decreased by 90% (untreated cells: 0.362 nM; treated cells: 32.8 nM). The Con A binding 
capacity, Bmax, was significantly reduced following sodium periodate treatment (125.8 Hz to 14.24 Hz). The ka 
and kd, association and dissociation rate constants, for Con A binding to sodium periodate treated rHER2 also 
increased.
The effect of tunicamycin treatment on sensitivity of cancer cells to DXR and growth factors. 
SKBR-3 cells were maintained in tunicamycin and the lectin WGA, conjugated to QDs, was used to monitor 
the reduction in glycosylation (Fig. 5A). The cells were cultured in tunicamycin (100 nM–1 μ M) over several 
passages (Fig. 5B) and the metabolic activity was assessed using an MTT assay When cells were exposed to 
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dual treatment with DXR (100 nM, 0.5 μ M, and 1 μ M) and tunicamycin a significant decrease in the metabolic 
activity was observed (student t-test, unpaired, P < 0.001). No significant difference in the metabolic activ-
ity was observed when the cells were cultured with DXR at 5 and 10 μ M and tunicamycin. The IC50 value for 
SKBR-3 cells treated with tunicamycin was determined: treated cells: 0.57 μ M DXR: untreated: 0.91 μ M DXR, 
Supplementary Figure 2. To further investigate the effect of glycosylation on cancer cell responsiveness to extrin-
sic factors SKBR-3 cells were maintained in tunicamycin and exposed to IGF-1 and EGF (Fig. 5C) and the cellular 
activity monitored using the MTT assay. Cells maintained in tunicamycin were significantly less responsive to 
IGF-1 alone (decreased responsiveness by 7%, paired t-test, p < 0.001) or in combination with EGF (decreased 
responsiveness by 6.3%, paired t-test, p < 0.001). Somewhat surprisingly, this observation was not made when 
the cells were maintained in tunicamycin and treated with EGF alone (Fig. 5C) despite apparent equal levels of 
EGFR in the tunicamycin treated cells (Fig. 5D). From these observations it can be surmised that inhibition of 
cellular glycosylation by tunicamycin treatment reduces cellular responsiveness to growth factors. Maintaining 
cells in tunicamycin reduced the N-linked glycosylation and resulted in a reduction in sensitivity to IGF-1 alone 
and IGF-1 in combination with EGF.
Discussion
The influence of N-linked glycosylation on cancer cell responsiveness to common cancer treatment modalities 
were explored in this study. In particular, the interaction between the biological (monoclonal antibody) treatment 
Herceptin with HER2 receptors on cancer cell surfaces and the sensitivity of cancer cells to the chemotherapeutic 
agent DXR was considered alongside the effect of glycosylation on cancer cell sensitivity to the growth factors 
EGF and IGF-1.
The lectins Con A and WGA were both utilised as tools for monitoring the N-linked glycosylation status of 
the rHER2 and the breast cancer cell lines. Con A binds mannose residues whilst WGA recognises both GlcNAc 
and sialic acid residues, as these glycans are present in N-linked oligosaccharides each lectin will provide infor-
mation on the N-linked glycosylation status of proteins and cells. At the outset, a range of breast cancer cell lines 
were incubated with FITC-labelled Herceptin, the relatively weak intensity of staining highlighted the inacces-
sibility of the Herceptin binding site on HER2 in contrast to the binding site for conventional anti- cerbB-2 
antibodies (such as utilised in this study). However, when SKBR3 cells were treated with sodium periodate the 
binding of Herceptin increased as a result of improved accessibility of the HER2 epitope. Changes in the kinetics 
Figure 1. Herceptin binding to cancer cells viewed using the Leica TCS SP2 confocal microscope. Four 
breast cancer cell lines BT474, ZR-751, MCF-7 and SKBR3 were incubated with FITC labelled Herceptin 
(green) for 1 hr and the nuclei were counterstained with 1 mM To-Pro3 (blue) as shown. Inset, lower, SKBR-3 
cells stained with rabbit anti- cerbB-2 and secondary goat-anti-rabbit antibody labelled with Alexa Fluor 488 
(green). The nuclei were counterstained as before (blue). Inset, upper, 3D z-stack of SKBR-3 cells stained with 
rabbit anti-cerbB-2 and secondary goat-anti-rabbit antibody labelled with Alexa Fluor 488 (green). The SKBR-3 
cells stained with the anti-cerbB-2 antibody show the increased accessibility of the HER2 epitope compared 
with accessibility of the HER2 epitope to Herceptin.
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of Herceptin binding were also observed after deglycosylation of both SKBR3 cells and the rHER2 protein. The 
dissociation constant, affinity (KD) of Herceptin to immobilised rHER2 protein (0.56 nM) and to SKBR-3 cells 
(0.51 nM), was consistent with previous reports obtained using surface plasmon resonance (SPR) technology 
(0.5 nM KD)30. Alterations in the cellular glycan repertoire following deglycosylation resulted in a significant 
increase in the Bmax reading. This data suggests that removal of glycans renders the Herceptin binding sites on 
HER2 more accessible, perhaps due to a lack of stearic hindrance from glycans present either on HER2 itself 
and/or, in the case of the study with the cell biosensor chip, on neighbouring macromolecules. Removal of the 
N-glycan residues from the HER2 receptor might lead to a decrease in stability of the Herceptin-HER2 complex 
and might explain the notable increase in the dissociation rate constant. A recent report comparing the kinetics of 
binding of Herceptin to SKBR-3 cells with a Herceptin-resistant and sensitive phenotype (analysed using surface 
plasmon resonance imaging) described an increase in both the ka and kd in the Herceptin-resistant cell popula-
tions, these changes in ka and kd are consistent with our findings31.
Figure 2. Herceptin and Con A binding to SKBR3 cells untreated and after treatment with 20 mM and 
40 mM sodium periodate for 1 h at room temperature. The cells were stained with FITC labelled Con A 
(green) (A) or FITC labelled Herceptin (green). The nuclei were counterstained with 1 mM To-Pro3 (blue). 
Immunofluorescence images showed a decrease in the binding of Con A in the cytoplasm and increased binding 
of Herceptin to the cell membrane following treatment of the cells with sodium periodate. Student t-test analysis 
of total cell fluorescence showed a significant difference between untreated (UT) and treated cells for (C) Con 
A (p < 0.001) binding and (D) Herceptin (p < 0.05) binding. Images were analysed using ImageJ (National 
Institute of Health) and total corrected cell fluorescence was calculated using the integrated fluorescence density 
(n = 10) after subtraction of the mean average fluorescence of background reading. NS; non significant.
SKBR-3 CELLS
ka (M−1s−1) kd (s−1) KD (nM) Bmax
Untreated 2.46 E+5 (± 9.41) 1.26E−4 (± 2.32 E−5) 0.512 (± 0.09) 6.83 (± 5.82 E−5)
20 mM sodium periodate 4.31 E+5 (± 7.0) 3.42 E−4 (± 1.9 E−5) 0.795 (± 0.04) 7.35 (± 1.37 E−3)
rHER2 PROTEIN
Untreated 3.36 E+5 (± 2 E+1) 1.91 E−4 (± 4.91 E−5) 0.56 (± 0.146) 42 (± 0.003)
20 mM sodium periodate 6.61 E+5 (± 1.12 E+1) 2.14 E−4 (± 1.4 E−7) 0.323 (± 0.2) 62.4 (± 0.014)
Table 1.  Kinetic parameters derived from sensograms of Herceptin binding to either SKBR3 cell surfaces 
or rHER2 protein using TraceDrawer software, either using 1:1 simple or 1:2 binding models. Mean average 
values ± SD, derived from two sensor chips for each condition and four analyte concentrations.
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A significant increase in the sensitivity of SBKR-3 cells to DXR and a decrease in sensitivity to IGF-1 alone and 
in combination with EGF were observed on treatment of the cells with tunicamycin. These findings provide evi-
dence of the importance of glycosylation and how it might affect the efficacy of therapeutics in breast cancer and 
also highlights the potential for approaches aimed at abrogating glycosylation as a means of rendering cancer cells 
more susceptible to cancer treatment modalities. Fluorescence images of cells stained with WGA-labelled QDs 
following treatment with tunicamycin showed the effectiveness of this approach for decreasing cellular glycosyl-
ation. The use of lectins conjugated to QDs to image glycosylation levels in cells has been reported elsewhere32 
and further work has shown their potential for exploring the relationship between glycosylation changes and 
metastatic potential in cancer33. The work performed here builds on a growing body of evidence suggesting that 
lectins conjugated to QDs may have widespread application as tools for cancer diagnostics. As the understanding 
of glycoproteomic changes in cancer biology grows future applications may involve QDs with more specific gly-
cosylation targets. MUC1 for example, has been identified as a possible nano-particle imaging target, with both 
prognostic value as well as therapeutic application34.
The human HER2 receptor has been predicted to be glycosylated with seven N-linked glycans 
(Supplementary Figure 1). N-linked glycosylation of HER2 is required for successful translocation of HER2 to the 
cell surface and acquisition of function35. The importance of N-linked glycosylation of HER2 for downstream signal-
ling via the MAPK pathway has also been shown previously36. When SKBR-3 cancer cells were treated with sodium 
periodate a significant increase in the binding of Herceptin was observed. QCM biosensor analysis showed that this 
was due to an increased rate of Herceptin binding and an increase in the Bmax, implying improved accessibility of 
the Herceptin binding domain on HER2 following protein deglycosylation. This increased accessibility is consistent 
with a de-masking of the Herceptin binding epitope of HER2 on cancer cell surfaces. Whilst the observed increase 
in Bmax may be due to deglycosylation of HER2 itself, it is also possible that deglycosylation of other neighbouring 
cell surface glycoproteins (for example, MUC4, HER1, HER3, HER4 and IGFR) might underlie the reason(s) for the 
Figure 3. Representative sensograms (black) illustrating real time binding of Herceptin onto SKBR3 cells 
grown on the QCM sensor chip surface (A,B) and rHER2 immobilised onto the biosensor surface (C,D). Cells 
were treated with 20 mM sodium periodate for 1 hour at room temperature. Herceptin binding was monitored 
using the Attana Cell 200. A COP-1 chip without cells was also used and the background binding data 
subtracted from the data for the cell chip. The association (105s) and dissociation (195s) phases of binding were 
monitored at a flow rate of 20 μ l/min and at 22 °C. The red curves represent the theoretical curve fitting using 
TraceDrawer software, either using 1:1 simple or 1:2 binding models. Herceptin was diluted in PBS running 
buffer and injected at concentrations of 8.58 nM, 17.61 nM, 34.32 nM and 68.64 nM. Regeneration with 10 mM 
glycine was performed between each analyte injection.
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increased accessibility of the Herceptin binding domain on HER2. When rHER2 was immobilised onto the QCM 
biosensor chip surface a similar observation was made further supporting the hypothesis that glycosylation affects 
the accessibility of the HER2 protein binding domain to Herceptin. The data obtained in this study concur with a 
recent report in which SKBR-3 and MCF-7 cells were treated with tunicamycin and for which an increased respon-
siveness of the cells to Herceptin was observed, correlating with increased cell cycle arrest and cellular apoptosis37.
Tunicamycin treatment of SKBR-3 cells resulted in a decreased response to the growth factor IGF-1 alone and 
in combination with EGF. This may be due to decreased IGFR-R1 function following deglycosylation as reported 
elsewhere38 or due to down-regulation in IGF-R1 receptor levels as observed when melanoma cells were main-
tained in tunicamycin39. A further possible mechanism for the increased sensitivity of SKBR-3 cells to DXR is that 
with reduced glycosylation the overall cellular glycocalyx offers less of a barrier to chemotherapeutic agents as 
maintenance of SKBR-3 cells in tunicamycin resulted in cancer cells that were more sensitive to treatment with 
DXR at a range of concentrations. No significant difference in the metabolic activity of the cells was observed at 
Figure 4. Representative sensorgrams (black) illustrating real time binding of Con A onto SKBR3 cells grown 
on the QCM sensor chip surface (A,B) and rHER2 immobilised onto the sensor surface. Cells were treated with 
20 mM sodium periodate for 1 hour at room temperature and Con A binding to cell surface was monitored 
using the Attana Cell 200. LNB-Carboxyl surface activated/deactivated was used as the reference surface. The 
association (105s) and dissociation (195s) phases of binding were monitored at a flow rate of 20 μ l/min and at 
22 °C. The red curves represent the theoretical curve fitting using TraceDrawer software, either using 1:1 simple 
or 1:2 binding models. Con A was diluted in PBS running buffer and injected at concentrations of 2.8 nM, 
5.6 nM, 11.1 nM and 22.3 nM. Regeneration was with 10 mM HCl, performed between each analyte injection.
SKBR-3 CELLS
ka (M−1s−1) kd (s−1) KD (nM) Bmax
Untreated 2.46 E+4 (± 11.92) 8.9 E−6 (± 6.23 E−5) 0.362 (± 0.07) 125.8 (± 0.007)
20 mM sodium periodate 5.8 E+4 (± 1.49 E+3) 1.93 E−3 (± 1.08 E−5) 32.8 (± 1.02) 14.24 (± 0.022)
rHER2 PROTEIN
Untreated 1.75 E+5 (± 3.62 E+1) 8.76 E−4 (± 1.48 E−6) 5.02 (± 0.03) 11.17 (± 0.08)
20 mM sodium periodate 1.51 E+5 (± 2.85 E+2) 1.89 E−4 (± 5.12 E−7) 1.25 (± 0.004) 5.03 (± 0.05)
Table 2.  Kinetic parameters derived from sensograms of Con A binding to either SKBR3 cell surfaces or 
rHER2 protein using TraceDrawer software, either using 1:1 simple or 1:2 binding models. Mean average 
values ± SD, derived from two sensor chips for each condition and four analyte concentrations.
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higher concentrations of DXR (5 and 10 μ M) and this may be due to the cytotoxicity of the DXR at these concen-
trations. The findings of this study provide additional evidence for the potential use of glycosylation inhibitors 
as a supplement to current chemotherapeutic regimens. Reports attest to the increased susceptibility of cancer 
cells to chemotherapeutic agents when treated with such inhibitors, for example, the multi-drug resistant ovar-
ian cancer cell line UWOV2 became responsive to vincristine, cisplatin and DXR on tunicamycin treatment40. 
Induction of cell cycle arrest and increased apoptosis has been reported following Herceptin treatment of breast 
cancer cells grown in vitro and in vivo and treated with tunicamycin30. Similarly, increased sensitivity of cancer 
cells to cisplatin both in vitro and in a cisplatin resistant (C3H/HE) mouse model in vivo has been reported fol-
lowing tunicamycin treatment41. The responses may be tumour/cell type specific, however, as it has been noted 
that tunicamycin treatment was associated with an increase in resistance to chemotherapy agents in hepatocel-
lular carcinoma cells42. Since tunicamycin has a broad effect on all N-linked glycoproteins, tunicamycin-induced 
inhibition of N-glycosylation may produce systemic side effects if used as a treatment modality although optimal 
tunicamycin doses which do not induce cell toxicity have been achieved using MCF-7/HER2 xenograft models30. 
Similarly, inhibition of N-linked glycosylation of the P-glycoprotein has been achieved without altering its func-
tion as a drug efflux pump43. Whole patient treatment with swainsonine to inhibit alpha mannosidase has shown 
the potential tolerability of this approach44 supporting the role for glycosylation inhibitors as combination thera-
pies for cancer45. The reduction in N-linked glycosylation of SKBR-3 cells also resulted in a reduced proliferative 
response to growth factors and increased sensitivity to DXR. The findings highlight the importance of the glyco-
caylx in the accessibility of the HER2 epitope to Herceptin as glycosylation occurs on many proteins and lipids 
this may affect many aspects of cancer cell biology and drug responsiveness (Fig. 6).
In conclusion, this study highlights the importance of cellular glycosylation on the binding of the drug 
Herceptin to the surface of cancer cells, the responsiveness of cancer cells to the chemotherapeutic agent DXR and 
sensitivity to growth factors. The findings illustrate the importance of glycosylation in modulating the respon-
siveness of cancer cells to treatments. The study also highlights a potential role for glycosylation inhibitors as 
(combination) treatments for breast cancer.
Figure 5. Representative fluorescent images of SKBR3 cells maintained in tunicamycin (1 μ g/ml) and stained 
with WGA conjugated QD at 4 °C for 3 h and SKBR-3 cells maintained in medium without tunicamycin and 
treated with the same volume of QD alone (A). The percentage survival of SKBR-3 cells maintained with/
without tunicamycin and following treatment with DXR (1 nM–10 μ M) the mean % cell survival was calculated 
assuming 100% survival for untreated cells (B). Cell stimulation as measured by % cell count of SKBR-3 cells 
maintained with/without tunicamycin and exposed to EGF, IGF alone or in combination (C). Western blot 
analysis of EGFR (HER1) and HER2 for SKBR-3 cells pre and post treatment with tunicamycin a faint band 
which may represent deglycoyslated HER2 in the tunicamycin treated cells is shown by the arrow (D). UT: 
Untreated, Tx: tunicamycin treated GAPDH levels were assessed as a gel loading control.
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Materials and Methods
Chemicals were obtained from Sigma-Aldrich, Poole, Dorset, UK, unless otherwise stated. All cell lines were 
recently obtained from the ATCC and are part of a collection of breast cancer cells held at the University of 
Westminster and University College London. The cells have been confirmed mycoplasma free. SKBR-3, MCF-7, 
ZR75–1 cells were subjected to short tandem repeat (STR) typing performed in-house using the Genome 
Lab Human STR Primer Set (Beckman Coulter, High Wycombe, UK). DNA samples were prepared using the 
high-pure PCR template preparation kit (Roche, Welwyn Garden City, UK). Fragment analysis was performed on 
a Beckman Coulter CEQ8800 Genetic Analyser and the STR genotype profile of each cell line was analysed using 
an online tool provided by the DMSZ collection of cell cultures https://www.dsmz.de/.
Cell culture. Four human breast cancer cell lines were used: SKBR3, MCF-7, BT474 and ZR-175. SKBR-3 is a 
human epithelial cell line that overexpresses the HER2 receptor29 and has been widely used for HER2 expression 
studies. BT474 is also a HER2 overexpressing cell line. Both MCF-7 and ZR-175 are known to be HER2 negative. 
SKBR-3 cells were cultured in McCoy’s 5 A medium with 2 mM L-glutamine (Lonza, Slough, UK) supplemented 
with 10% (v/v) foetal calf serum (FCS; Biosera, Ringmer, UK). The remaining cell lines were grown in DMEM 
(Lonza, Slough, UK) supplemented with 10% (v/v) FCS. All cells were incubated at 37 °C in humidified atmos-
phere in a 5% v/v CO2 incubator. The cells were passaged at the split-ratio recommended by the ATCC and were 
seeded into 6-well plates using standard cell culture techniques. All the experiments were performed within a 
total of ten passages.
Immuno-fluorescent staining and confocal microscopy. The accessibility of the HER2 receptor to 
Herceptin was investigated in BT474, ZR-751, MCF-7 and SKBR-3 cells using fluorescein isothiocyanate (FITC) 
labelled Herceptin (Roche, Welwyn Garden City, UK, 160218-150 mg) prepared using a FITC labelling kit accord-
ing to the manufacturer’s recommendations (Piercenet, Illinois, USA) this included a desalting step on a PD-10 
column (GE Healthcare, Amersham, UK). The cells were grown to 80% confluence on the surface of 6 well plates, 
washed with phosphate buffered saline (3x, PBS, pH 7.6), fixed in 3.7% formaldehyde/PBS, again washed with 
PBS and blocked with 5% w/v bovine serum albumin (BSA) for 30 min. Fixation of cells in formaldehyde renders 
the HER2 epitope inaccessible to Herceptin. A range of treatment methods were tested for effective Herceptin 
staining; treatment of cells with porcine trypsin (1 mg/ml) for 20 min at 37 °C was established as the most effective 
antigen-retrieval approach. Cells were incubated with FITC-labelled Herceptin, 10 μ g/ml, for 1 hour in the dark. 
In addition, SKBR-3 cells were stained with anti-cerbB-2 antibody, 0.614 μ g/ml, for 1 hour at room temperature 
Figure 6. Schematic diagram showing the extracellular domain of the SKBR-3 cells, the HER2 protein prior 
to (A) and after (B) glycan removal. Masking of Herceptin binding to the juxtamembrane domain of HER2 
receptor and DXR access to transporter proteins (eg: RL1P76) by large membrane glycoproteins such as mucins 
(MUC4) or N-linked glycans on the receptor.
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(Abcam, Cambridge, UK) and secondary anti-rabbit IgG, 4 μ g/ml for 1 hour at room temperature (Alexa Fluor 
488, Abcam, Cambridge, UK). Lectin staining was performed in the absence of trypsinisation with rhodamine 
or FITC labelled Con A or WGA (10 μ g/ml) (Vector Labs, Peterborough, UK) for 1 h. Cells were counterstained 
with the nuclear stain To-Pro-3 (1 mM) for 30 min after pre-treatment with RNase A (10 μ g/ml) for 20 min. 
Images were acquired by sequential scanning using a Leica TCS SP2 confocal system (Leica Microsystems, Milton 
Keynes, UK) and analysed using ImageJ (National Institute of Health, Maryland, U.S.A.). Z-stacks were taken 
with each slice thickness 1 μ m. The total corrected cell fluorescence was calculated using the integrated fluores-
cence density (n = 10) following subtraction of the mean background fluorescence reading.
Deglycosylation. The antibiotic tunicamycin was used to inhibit cellular glycosylation at a final concentra-
tion of 1 μ g/ml; cells were maintained in the treatment medium ≥ 7 passages. The effectiveness of this step was 
assessed by fluorescent lectin cytochemistry using WGA conjugated to quantum dots (QD) prepared, in brief, 
using cadmium chloride and sodium tellurite to form the core, with a mercaptosuccinic acid coating, in sodium 
borate/citrate buffer, pH 7.2 and sodium borohydride as a reductant46,47 the QDs were washed, suspended in PBS 
and refrigerated at 2 °C until use. Where chemical deglycosylation was employed to oxidise the glycans, cells were 
treated with 20–60 mM sodium periodate, pH 5.5, for 1 h48. The effectiveness of this step was assessed by fluores-
cent lectin cytochemistry with Con A as described above.
Biosensor experiments. QCM biosensor experiments were performed using an Attana Cell 200 instru-
ment using consumables and software (Attana, Stockholm, Sweden) unless otherwise stated. 40,000 SKBR-3 cells 
were seeded onto a cell culture compatible polystyrene coated sensor surface (COP-1) allowed to settle and main-
tained under standard cell culture conditions for 18 h, the cell chips were washed in PBS (3X) and fixed in fresh 
3.7% v/v formaldehyde/PBS for 20 min at room temperature. To evaluate the cell coverage, the nuclei were stained 
with To-Pro3 as described above and visualised using confocal microscopy. A COP-1 surface processed the same 
way as the cell chip (without cells) was used as a negative control.
rHER2 protein (Sino Biologics Inc., Beijing, China), 2 μ g, was reduced using 10 mM DTT and immobilised 
onto an LNB-Carboxyl sensor surface by amine coupling using EDC and sNHS according to the manufacturer’s 
instructions (Attana, Stockholm, Sweden). Remaining active groups were deactivated using 1 M ethanolamine 
for 300 sec. A LNB-Carboxyl surface activated and deactivated as above was used as the reference surface. Two 
fold serial dilutions of Herceptin (8.5 nM–17.1 nM) and Con A (2.7 nM–44 nM) were used to study the kinetics of 
binding to immobilised HER2 and to the cell surface at a flow rate of 20 μ l/min at 22 °C. Between each Herceptin 
dilution the surface was regenerated using 10 mM glycine pH 2.2 and between each Con A dilution the surface 
was regenerated using 10 mM HCl; the same procedure was followed to regenerate the cell chip surfaces.
The changes in the frequency of the sensor surface resonance (Δ F) during the binding experiments was 
recorded using the Attestar software and the data were analysed using the Evaluation (Attana, Stockholm, 
Sweden) and TraceDrawer software (Ridgeview Instruments AB, Stockholm, Sweden). To obtain values for the 
specific binding response, the background binding to the reference surfaces were subtracted from the experimen-
tal surfaces. 1:1 or 1:2 binding models were used to calculate the kinetic parameters including the rate constants 
(ka, kd), dissociation constant (KD) and the maximum binding capacity (Bmax). All biosensor experiments were 
repeated using a second and third set of sensor surfaces prepared using the same procedure.
Cell Inhibition/Stimulation and MTT assays. Cells were seeded onto 24-well plates in media (as above) 
at 5 × 104 cells per well for inhibition assays or 2.5 × 104 cells per well for growth assays, and allowed to settle for 
24 hours. The cells were semi-synchronized to the same phase of the cell cycle by replacing the medium with 
McCoy’s 5 A with 2 mM L-glutamine and incubating for a further 24 hours. The medium was supplemented with 
0.5% v/v dextran-coated charcoal stripped serum and EGF and IGF-1 were added alone or in combination to a 
final concentration of 1 ng/ml, or 50 ng/ml respectively. The metabolic activity of the cells was assessed using an 
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay in a 96-well plate format. MTT was 
used at a final concentration of 0.5 mg/ml per well followed by incubation at 37 °C for 2 hours (n = 8). The exper-
iments were repeated under identical conditions on separate days. The insoluble tetrazolium salt was reduced to 
the soluble formazan dye by addition of 600 μ l dimethyl sulphoxide and further incubation of the plate for 10 min 
at room temperature. The optical density was read using a colorimetric plate reader (BioTek Instruments, USA) 
at 570 nm absorbance. The IC50 values of DXR for both treated and untreated cells were calculated using the 
GraphPad Prism Software.
Protein extraction, SDS-PAGE and Western blotting. Cells were harvested at 80% confluence into 
radio-immunoprecipitation assay (RIPA) buffer containing protease inhibitors (Roche Diagnostics, Germany). 
The cellular debris was pelleted by centrifugation (20,000 ×g for 5 min) and protein concentration quantified 
using the Lowry protein assay. Equal quantities of protein (20 μ g) heat-denatured in the presence of 0.03% v/v 
β -mercaptoethanol and 1X NuPAGE LDS Sample Buffer (Fisher Scientific, Loughborough, UK) in a total of 30 μ l 
was loaded onto a NuPAGE Novex 4–12% gradient Bis-Tris gel (Fisher Scientific, Loughborough, UK) and sep-
arated by electrophoresis. Western blotting was performed by transfer of the separated proteins by electroblot to 
a (0.22 μ m) PVDF (polyvinylidene fluoride) membrane (BioRad, Hemel Hempstead, UK), the membrane was 
blocked using 2.5% w/v BSA in PBS − 0.05% v/v Tween-20 for 30 min.
Protein expression levels were confirmed using primary anti-HER2/Neu mouse monoclonal antibody (Santa 
Cruz; Dallas, Texas, US sc-08, 1:500 dilution in 1% w/v BSA-Tween) and anti-EGFR mouse monoclonal antibody 
(Santa Cruz; Dallas, Texas, US, sc-374607 1:1000 dilution in 1% w/v BSA-Tween) followed by goat anti-mouse 
horseradish peroxidase conjugated antibody (Santa Cruz Dallas, Texas, US sc-2005; 1:2500 dilution in 1% v/v 
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BSA-Tween) at room temperature. The HRP reaction was detected using ClarityTM Western ECL substrate and 
visualised using ChemiDoc XRS with Image Lab software (Bio-Rad, Hemel Hempstead, UK).
Statistical Analysis. Microsoft Excel 2013 was used to generate graphical data and descriptive statistics. 
IBM SPSS Statistics version 21 was used for all other statistical analysis.
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